dc.contributor.author | Perez-Lopez, R | |
dc.contributor.author | Mateo, J | |
dc.contributor.author | Mossop, H | |
dc.contributor.author | Blackledge, MD | |
dc.contributor.author | Collins, DJ | |
dc.contributor.author | Rata, M | |
dc.contributor.author | Morgan, VA | |
dc.contributor.author | Macdonald, A | |
dc.contributor.author | Sandhu, S | |
dc.contributor.author | Lorente, D | |
dc.contributor.author | Rescigno, P | |
dc.contributor.author | Zafeiriou, Z | |
dc.contributor.author | Bianchini, D | |
dc.contributor.author | Porta, N | |
dc.contributor.author | Hall, E | |
dc.contributor.author | Leach, MO | |
dc.contributor.author | de Bono, JS | |
dc.contributor.author | Koh, D-M | |
dc.contributor.author | Tunariu, N | |
dc.date.accessioned | 2016-08-23T10:37:36Z | |
dc.date.issued | 2017-04-01 | |
dc.identifier.citation | Radiology, 2017, 283 (1), pp. 168 - 177 | |
dc.identifier.issn | 0033-8419 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/71 | |
dc.identifier.eissn | 1527-1315 | |
dc.identifier.doi | 10.1148/radiol.2016160646 | |
dc.description.abstract | Purpose To determine the usefulness of whole-body diffusion-weighted imaging (DWI) to assess the response of bone metastases to treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). Materials and Methods A phase II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor olaparib in mCRPC included a prospective magnetic resonance (MR) imaging substudy; the study was approved by the institutional research board, and written informed consent was obtained. Whole-body DWI was performed at baseline and after 12 weeks of olaparib administration by using 1.5-T MR imaging. Areas of abnormal signal intensity on DWI images in keeping with bone metastases were delineated to derive total diffusion volume (tDV); five target lesions were also evaluated. Associations of changes in volume of bone metastases and median apparent diffusion coefficient (ADC) with response to treatment were assessed by using the Mann-Whitney test and logistic regression; correlation with prostate-specific antigen level and circulating tumor cell count were assessed by using Spearman correlation (r). Results Twenty-one patients were included. All six responders to olaparib showed a decrease in tDV, while no decrease was observed in all nonresponders; this difference between responders and nonresponders was significant (P = .001). Increases in median ADC were associated with increased odds of response (odds ratio, 1.08; 95% confidence interval [CI]: 1.00, 1.15; P = .04). A positive association was detected between changes in tDV and best percentage change in prostate-specific antigen level and circulating tumor cell count (r = 0.63 [95% CI: 0.27, 0.83] and r = 0.77 [95% CI: 0.51, 0.90], respectively). When assessing five target lesions, decreases in volume were associated with response (odds ratio for volume increase, 0.89; 95% CI: 0.80, 0.99; P = .037). Conclusion This pilot study showed that decreases in volume and increases in median ADC of bone metastases assessed with whole-body DWI can potentially be used as indicators of response to olaparib in mCRPC. Online supplemental material is available for this article. | |
dc.format | Print-Electronic | |
dc.format.extent | 168 - 177 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | RADIOLOGICAL SOC NORTH AMERICA | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Bone Neoplasms | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Piperazines | |
dc.subject | Phthalazines | |
dc.subject | Antineoplastic Agents | |
dc.subject | Diffusion Magnetic Resonance Imaging | |
dc.subject | Treatment Outcome | |
dc.subject | Prospective Studies | |
dc.subject | Pilot Projects | |
dc.subject | Image Processing, Computer-Assisted | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Male | |
dc.subject | Whole Body Imaging | |
dc.subject | Biomarkers, Tumor | |
dc.title | Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-08-01 | |
rioxxterms.versionofrecord | 10.1148/radiol.2016160646 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Radiology | |
pubs.issue | 1 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 283 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Clinical Trials & Statistics Unit | |
icr.researchteam | ICR-CTSU Urology and Head and Neck Trials Team | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
icr.researchteam | Computational Imaging | |
icr.researchteam | Magnetic Resonance | |
dc.contributor.icrauthor | Mossop, Helen | |
dc.contributor.icrauthor | Blackledge, Matthew | |
dc.contributor.icrauthor | Collins, David | |
dc.contributor.icrauthor | Rescigno, Pasquale | |
dc.contributor.icrauthor | Porta, Nuria | |
dc.contributor.icrauthor | Hall, Emma | |
dc.contributor.icrauthor | Leach, Martin | |
dc.contributor.icrauthor | De Bono, Johann | |